share_log

HC Wainwright & Co. Reiterates Buy on Acer Therapeutics, Maintains $12 Price Target

Benzinga ·  Mar 28, 2023 22:50

HC Wainwright & Co. analyst Vernon Bernardino reiterates Acer Therapeutics (NASDAQ:ACER) with a Buy and maintains $12 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment